Iduna Biotechnology is a biotechnology company developing small molecule therapeutics that enhance chaperone-mediated autophagy (CMA) for the treatment of Parkinson's disease and related neurodegenerative disorders. The company's name references Iduna, the Norse goddess associated with apples of youth and rejuvenation, reflecting its mission to restore cellular homeostasis and prevent neurodegeneration[1].
Iduna's approach targets LAMP2A (lysosome-associated membrane protein 2A), the rate-limiting receptor for CMA, which is specifically impaired in Parkinson's disease. The company has identified small molecule activators of LAMP2A that can restore CMA function and promote clearance of toxic alpha-synuclein aggregates.
CMA is a selective autophagy pathway that degrades cytosolic proteins through direct translocation across the lysosomal membrane. LAMP2A forms multimeric translocation complexes that recognize and import CMA substrates[2].
Key findings in PD:
Iduna develops LAMP2A agonists that:
| Drug | Mechanism | Phase | Indication |
|---|---|---|---|
| IDU-101 | LAMP2A agonist | Preclinical | Parkinson's disease |
| IDU-102 | LAMP2A agonist | Discovery | Multiple System Atrophy |
| IDU-201 | Alpha-synuclein degrader | Discovery | PD with dementia |
Iduna's platform has demonstrated:
Iduna uses a proprietary cell-based screening platform to identify LAMP2A modulators:
The company has validated LAMP2A as a therapeutic target through:
| Company | Target | Approach | Status |
|---|---|---|---|
| Iduna Biotechnology | LAMP2A | Small molecule agonist | Preclinical |
| LysoNext | LAMP2A | Gene therapy | Discovery |
| Vanqua Bio | LAMP2A | Small molecule | Phase 1 |
| Denali | GBA1/TFEB | Small molecule | Phase 2 |
Iduna has assembled leading experts in autophagy and neurodegeneration:
Chaperone-mediated autophagy in Parkinson's disease: LAMP2A as therapeutic target. Nat Rev Neurol. 2022. ↩︎
Koga H, et al. LAMP2A regulates alpha-synuclein clearance in neurons. Nat Neurosci. 2018. ↩︎
Martinez A, et al. Chaperone-mediated autophagy dysfunction in Parkinson's disease. J Neurosci. 2017. ↩︎